Institutions / Ghost Tree Capital, LLC
Ghost Tree Capital, LLC
CIK 1595851 · Institution · as of Sep 30, 2024
Portfolio value
$293.22M
Positions
51
As of
Sep 30, 2024
Portfolio trend
Portfolio value
$293.22M+2.0%Positions
51-13.6%Holdings
Sep 30, 2024View all 51 →
| Company | Value | % of portfolio |
|---|---|---|
| Biohaven Ltd | $17.43M | 5.9% |
| Sarepta Therapeutics, Inc.SRPT | $14.99M | 5.1% |
| Novo-Nordisk a SNVO | $13.10M | 4.5% |
| Blueprint Medicines CorpBPMC | $12.95M | 4.4% |
| Axsome Therapeutics, Inc.AXSM | $12.13M | 4.1% |
| Tarsus Pharmaceuticals, Inc.TARS | $11.51M | 3.9% |
| IsoRay, Inc.CATX | $10.01M | 3.4% |
| CG Oncology, Inc.CGON | $9.43M | 3.2% |
| Roivant Sciences Ltd.ROIV | $9.23M | 3.1% |
| Vaxcyte, Inc.PCVX | $9.14M | 3.1% |
| Viking Therapeutics, Inc.VKTX | $8.86M | 3.0% |
| Syndax Pharmaceuticals IncSNDX | $8.66M | 3.0% |
| Janux Therapeutics, Inc.JANX | $8.63M | 2.9% |
| Ascendis Pharma A/SASND | $7.84M | 2.7% |
| Crinetics Pharmaceuticals, Inc.CRNX | $7.67M | 2.6% |
| Capnia, Inc.CAPN | $7.57M | 2.6% |
| Tg Therapeutics, Inc.TGTX | $7.25M | 2.5% |
| Rezolute, Inc.RZLT | $7.15M | 2.4% |
| Phathom Pharmaceuticals, Inc.PHAT | $6.78M | 2.3% |
| MoonLake ImmunotherapeuticsMLTX | $6.47M | 2.2% |
| Olema Pharmaceuticals, Inc.OLMA | $6.39M | 2.2% |
| Immunovant, Inc.IMVT | $6.13M | 2.1% |
| INSMED IncINSM | $5.47M | 1.9% |
| Edgewise Therapeutics, Inc.EWTX | $5.20M | 1.8% |
| Replimune Group, Inc.REPL | $4.93M | 1.7% |
Activity
Sep 30, 2024View full history →
InsidersInstitutions
This fund's quarter-over-quarter position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2023 as of | Trim Other (per filing) | 75615P103 | $-39.09M | -430K -86.00% | 70,000 2.17% of portfolio | medium |
| Q4 2020 as of | New Other (per filing) | Syndax Pharmaceuticals Inc common | $30.02M | +1.4M | 1,350,000 10.24% of portfolio | medium |
| Q4 2020 as of | New Other (per filing) | 89620X506 | $28.68M | +1.9M | 1,950,000 9.78% of portfolio | medium |
| Q4 2020 as of | New Other (per filing) | Inotek Pharmaceuticals Corp common |